NATIONAL
HEALTHCARE 2023
Business programme
ORGANIZATION OF DOMESTIC PRODUCTION OF BLOOD PRODUCTS AS A CONTRIBUTION TO ENSURING THE SAFETY OF THE NATIONAL HEALTH SYSTEM
- 01.12.2023
- 16:15–17:45
- VDNH, 75 pavilion, Small hall 1
- Broadcast
Drugs obtained from blood plasma are considered vital and essential medicines. More than a million patients in Russia need them every year. At present, the domestic market for blood products is directly dependent on imports. Given the lack of domestic production facilities and the constant need to make purchases abroad, the health of Russia’s citizens and, consequently, its national security is dependent on external economic conditions. Amidst the current global challenges, expanding and improving the production of medicines derived from blood plasma is a top priority for Russia’s development. In order to eliminate the domestic healthcare industry’s dependence on imported medicines and strengthen national security, Russia needs to achieve self-sufficiency in the production of basic blood products by expanding the presence of Russian medicines derived from blood plasma on the domestic pharmaceutical market, create modern industrial production facilities for medicines derived from blood plasma, and increase the amount of blood plasma purchases in order to create a stable supply of raw materials for drug production by modernizing plasma centres and building technological facilities for plasma fractionation. How can we effectively increase the donation of blood and its components at the federal and regional levels? What alternative methods of blood-saving technologies exist? What are the key focuses of Russia’s state policy for increasing purchases of blood plasma for drug production? What support measures will facilitate the regions’ involvement in the project to build plasma centres? How can we accelerate the expansion of domestic drugs derived from blood plasma on the Russian market?
Panellists
Tatyana Gaponova
Victoria Manakova
Andrey Plutnitsky
Alexander Pshennikov
